


RECEIVED

RECEIVED  
NOV 20 2001  
TECH CENTER 1600/200  
TECHNOLOGY CENTER 2800

RECEIVED  
DEC 27 2001  
TECH CENTER 1600/2900



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of: ) Art Unit:  
Soren NIELSEN et al )  
U.S. App. No.: 09/845,717 ) Washington, D.C.  
National Filing Date: May 2, 2001 ) October 29, 2001  
For:METHODS OF TREATMENT OF... ) Docket No.:NIELSEN3B

PRELIMINARY AMENDMENT

Honorable Commissioner for Patents and Trademarks  
Washington, D.C. 20231

Sir:

Contemporaneous with the filing of this case and prior to calculation of the filing fee, kindly amend as follows:

IN THE CLAIMS

5. (Amended) Method according to claim 1 wherein the dosage of  $\alpha$ -MSH and/or of an  $\alpha$ -MSH equivalent and EPO and/or an EPO equivalent is administered as a single dosage, regular or continued administration, or as a sequential administration.

6. (Amended) Method according to claim 1 wherein condition is caused by an infection.

7. (Amended) Method according to claim 1 wherein the condition is caused by a cancer or a by premalignant disorder.

8. (Amended) Method according to claim 1 wherein the  $\alpha$ -MSH equivalent is a substance acting on the  $\alpha$ -MSH receptor and/or on the melanocortin receptor.